Provided by Integrity Continuing Education, Inc.
This program has been developed in collaboration with HealthHIV.
Supported by an educational grant from Gilead Sciences, Inc.
Human immunodeficiency virus (HIV) infection was first documented in the United States in 1981. Since that time, significant strides have been made in the prevention and treatment of the condition. Screening is paramount in identifying early infection and is now a routine component of care, and appropriate management with combination antiretroviral therapy (ART) extends patients’ lives, sometimes for many years. However, therapy is lifelong and complicated by pill burden, cost, adverse effects, drug interactions, and disparities. This plot-your-own-course activity covers evidence/guidelines for ART optimization in treatment-experienced patients with HIV and provides an overview of emerging antiretrovirals (ARVs).
Ian Frank, MD
Professor of Medicine
Department of Medicine/Infectious Diseases
University of Pennsylvania
Philadelphia, Pennsylvania
Monica Gandhi, MD, MPH
Professor of Medicine and Associate Chief
Department of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California San Francisco
Medical Director
Department of Medicine; Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California
Andrés Henao-Martínez, MD
Associate Professor
Department of Medicine
University of Colorado
Aurora, Colorado
This educational activity has been designed to meet the needs of US-based HIV specialty clinicians and infectious disease physicians involved in managing care for patients who are at risk for or living with HIV.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2022 through June 21, 2023, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Internet
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Ian Frank, MD
Consultant: Bristol Myers Squibb, Gilead Sciences, Janssen, Merck, ViiV
Research: Janssen, Moderna, Pfizer, Sanofi
Monica Gandhi, MD, MPH has no real or apparent conflicts of interest to disclose
Andrés Henao-Martínez, MD has no real or apparent conflicts of interest to disclose.
Integrity Continuing Education, Inc. staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.